\contentsline {figure}{\numberline {1}{\ignorespaces Sequential treatment strategies of interest to be compared with the model\relax }}{7}{figure.caption.2}
\contentsline {figure}{\numberline {2}{\ignorespaces Model structure with 4 states describing development of disease over time for a sequence starting with 1L, followed by 2L and 2L+ treatment; 2L+ treatment is captured with the L2 progression state\relax }}{10}{figure.caption.3}
\contentsline {figure}{\numberline {3}{\ignorespaces Alternative model structure with 3 states describing development of disease over time for a treatment sequence starting with 1L until death; 2L and 2L+ treatment is captured with the progression state\relax }}{11}{figure.caption.4}
\contentsline {figure}{\numberline {4}{\ignorespaces Relationship between stable disease (S), progression (P) and death (D) as used in the multi-state network meta-analysis model\relax }}{16}{figure.caption.7}
\contentsline {figure}{\numberline {5}{\ignorespaces First line estimates of hazard ratios from stable to progression relative to gefitinib from the multi-state network meta-analysis\relax }}{18}{figure.caption.8}
\contentsline {figure}{\numberline {6}{\ignorespaces First line estimates of progression-free survival and overall survival with gefitinib from multi-state meta-analyses\relax }}{18}{figure.caption.9}
\contentsline {figure}{\numberline {7}{\ignorespaces First line estimates of progression-free survival and overall survival for the competing interventions obtained with the multi-state network meta-analysis\relax }}{19}{figure.caption.10}
\contentsline {figure}{\numberline {8}{\ignorespaces Second line estimates of progression-free survival and overall survival from the multi-state network meta-analysis\relax }}{21}{figure.caption.11}
